




ixico.com

IXICO plc

Placing – Scaling technology to increase shareholder value



Non-regulated disclaimer 1/2



This presentation has been prepared by IXICO plc ("**IXICO**" or the "**Company**") and is for information purposes only. This presentation has been produced solely to provide a preliminary basis for potential investors to consider whether to pursue an acquisition of securities in the event that the Company decides to proceed with a proposed placing ("**Placing**") of ordinary shares of £0.01 each in the capital of the Company (the "**Shares**") and admission of the Shares to the AIM market of London Stock Exchange plc in accordance with the AIM Rules for Companies ("**Admission**").

This presentation and/or any further information made available by, or on behalf of, IXICO, Cavendish Capital Markets Limited ("**Cavendish**") or any of their respective affiliates, or any of their respective directors, officers, partners, employees, agents, affiliates or advisers (collectively "**Representatives**") relating to the Company or its group does not, and is not intended to, constitute or form part of any offer for sale or subscription or any solicitation, inducement or recommendation for any offer to purchase or subscribe for any securities, options, futures, or other derivatives related to securities nor shall it or any part of it form the basis of or be relied upon in connection with any contract or commitment whatsoever relating to the Company or any part of, or affiliate to, the Company's broader group. The Placing does not constitute a public offer of transferable securities in the United Kingdom (the "**UK**") pursuant to Regulation 21 of The Public Offers and Admissions to Trading Regulations 2024 ("**POATRs**") and accordingly no prospectus will be required in connection with the Placing.

This presentation is being communicated or distributed within the UK only to persons to whom it may lawfully be communicated. The contents of this presentation are not prescribed by securities laws and have not been approved for the purposes of section 21 of the Financial Services and Markets Act 2000 (as amended) ("**FSMA**"). This presentation is for distribution to persons in the UK (i) who are qualified investors within the meaning of Paragraph 15 of Part 2 of Schedule 1 of the POATRs and who also (a) have professional experience in matters relating to investments and who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "**Order**"); or (b) fall within Article 49(2) of the Order (including certain high net worth companies, unincorporated associations or partnerships and the trustees of high value trusts, or other respective directors, officers or employees as described in Article 49 of the Order); or (c) are other persons to whom this presentation, for the purposes of section 21 of FSMA, can otherwise lawfully be made without further action (all such persons together being "**Relevant Persons**"). Any other person who receives this document should not rely or act upon it. If you have received the Presentation and you are not such a person, you should not rely on the Presentation nor take any action upon it and should immediately return it to the Company. Otherwise, by accepting the Presentation and not immediately returning it to the Company, the recipient confirms, represents and warrants to the Company and to Cavendish that they are a person who falls within one of the categories of person described above and that the Presentation may be delivered to the recipient without contravention of any law. Information contained in this presentation should not be relied upon as advice to buy or sell or hold securities or as an offer to sell such securities and is in any event not intended for the use of nor should be relied upon by any person who is not a Relevant Person. This presentation does not take into account, nor does it provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person.

The information contained in this presentation is highly confidential and may constitute inside information for the purposes of the Criminal Justice Act 1993 ("**CJA 1993**") and the EU Market Abuse Regulation (2014/596/EU) which is part of UK law by virtue of the EUWA ("**MAR**"). You should not use this information as a basis for your behavior in relation to any financial instruments (as defined in MAR), as to do so could amount to a criminal offence of insider dealing under the CJA 1993 or a civil offence of insider dealing for the purposes of MAR or other applicable laws and/or regulations in other jurisdictions. This presentation and the information contained in this presentation is highly confidential and must not be copied, reproduced, published, distributed or disclosed in any way in whole or in part for any purpose to any other person without the prior written consent of IXICO. You shall treat and safeguard as strictly private and confidential all information contained in this presentation and take all reasonable steps to preserve such confidentiality. You shall not use this presentation, or the information contained herein in any manner detrimental to the Company. Your acceptance of the Presentation constitutes your agreement to (i) keep confidential all the information contained herein, as well as any information derived by you from the information contained herein (collectively, "**Confidential Information**") and not disclose any such Confidential Information to any other person, (ii) not use any of the Confidential Information for any purpose other than to evaluate your investment in the Company, (iii) not copy this document without the Company's prior consent, and (iv) promptly return this document and any copies hereof to the Company upon the Company's request.

Recipients of the Presentation have been requested to, and have confirmed that: (a) where the market sounding is being conducted by recorded telephone lines or audio or video recording, they have agreed to the recording of any such communication; (b) they are the person entrusted by the potential investor to receive the market sounding; and (c) they have agreed to receive the market sounding in the knowledge that they will be receiving information that the Company considers to be inside information for the purposes of Article 11(5)(a) of MAR and that, in accordance with Article 11(7) of MAR, they are required to assess for themselves whether they are in possession of inside information and when they cease to be in possession of inside information. The MAR and the market abuse regime under Part VIII of FSMA each set out obligations and restrictions regarding the use of inside information. Without limiting the obligations and restrictions imposed under the MAR and FSMA, by receiving the Presentation, you agree that you must not deal in (or encourage another person to deal in) the Company's (or any other company's) shares or securities or base any behaviour on such information until such information has ceased to be inside information.

This presentation is being provided to you for your own information and may not be distributed, published, reproduced or otherwise made available to any other person, in whole or in part, for any purposes whatsoever. In particular, it should not be distributed to or otherwise made available to persons with addresses in Canada, Australia, Japan, the Republic of South Africa or the United States, its territories or possessions or in any other jurisdiction outside of the UK where such distribution or availability may lead to a breach of any law or regulatory requirements. The distribution of this presentation in other jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction and neither IXICO nor Cavendish accepts any liability whatsoever for any such violations. The information contained in this presentation is given at the date of its publication and is subject to updating, revision and amendment. Further, it does not purport to be all inclusive or to contain all the information that may be required to evaluate the Company, the Shares and the Placing. In particular, the proposals referred to herein are tentative and are subject to verification, material updating, revision and amendment. Whilst the Company reasonably believes that the facts stated in this presentation are accurate and that any forecasts, opinions and expectations contained herein are fair and reasonable, Cavendish has not independently verified the contents of this presentation, and no reliance whatsoever should be placed on them. Accordingly, no representation or warranty, express or implied, is made by any person (including the Company, Cavendish or Representatives) as to the fairness, accuracy, completeness or

Non-regulated disclaimer 2/2



correctness of the information or opinions contained herein and each recipient of this presentation must make their own investigation and assessment of the matters contained herein. Any person who is in doubt about the Placing should consult with an independent financial adviser authorised under FSMA, who specialises in advising on the acquisition of shares and other securities, if that person is in the United Kingdom, or any appropriately authorised person under applicable laws, if that person is located in any other jurisdiction.

This presentation contains forward-looking statements that reflect IXICO's current expectations regarding future events, its liquidity and its subsidiary undertakings and the results of its operations, as well as its working capital requirements and future capital raising activities. Forward-looking statements involve substantial known and unknown risks, uncertainties and other important factors beyond the control of the Company (including, but not limited to, future market conditions, legislative and regulatory changes, the actions of governmental regulators, changes in the political, social and/or economic framework in which the Company operates). No representation or warranty is given, and to the fullest extent permitted by law no responsibility or liability is accepted by or on behalf of the Company, Cavendish or their Representatives, as to the achievement or reasonableness of any future projections or the assumptions underlying them, or any forecasts, estimates, or statements as to prospects contained or referred to in this presentation. Actual events or results or actual performance of the Company could differ materially from expectations embodied in forward-looking statements. Accordingly, you should not rely on any forward-looking statements or financial projections and neither the Company nor Cavendish nor their respective Representatives accept any obligation to disseminate any updates or revisions to such forward-looking statements or any other statements in the presentation.

Cavendish, which is authorized and regulated in the UK by the Financial Conduct Authority, is acting exclusively as nominated adviser and bookrunner for the Company for the purposes of the AIM Rules for Nominated Advisers and the AIM Rules for Companies and for no one else in relation to the Placing and Admission. Cavendish will not regard any other person (whether or not a recipient of this document) as its client in relation to the Placing and/or Admission and will not be responsible to anyone other than the Company for providing the protections afforded to its clients or for providing any advice in relation to this presentation, the Placing and/or Admission. The responsibilities of Cavendish, as nominated adviser, are owed solely to the London Stock Exchange plc and are not owed to the Company or to any director or any other person and accordingly no duty of care is accepted in relation to them.

To the fullest extent permitted by law, no responsibility or liability whatsoever is accepted by any person for any loss howsoever arising from any use of, or in connection with, this presentation or its contents or otherwise arising in connection therewith. To the fullest extent permitted by law and apart from any legal or regulatory responsibilities and liabilities, which may be imposed upon IXICO or Cavendish, or under the regulatory regime of any jurisdiction where exclusion of liability under the relevant regulatory regime would be illegal, void or unenforceable, each of IXICO and Cavendish severally disclaims all and any responsibility or liability, whether arising in tort, contract or otherwise, which they might otherwise have (and whether arising directly or indirectly) in respect of this presentation. None of IXICO or Cavendish undertakes any obligation to update or to correct any inaccuracies which may become apparent in this presentation however each of IXICO and Cavendish reserves the right (without accepting any obligation to do so) to amend, replace or update the information contained in this presentation at any time and to provide recipients with access to, or notification of, such amended information.

The Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "**U.S. Securities Act**") or under any laws of, or with any securities regulatory authority of, any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, in, into or within the United States or to or for the account or benefit of U.S. Persons (as defined in Regulation S under the U.S. Securities Act ("**Regulation S**")) (a "**U.S. Person**") except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction in the United States. Outside the United States, the securities may be sold to persons who are not U.S. Persons pursuant to Regulation S. No public offering of Shares is being made in the United States.

Solely for the purposes of the product governance requirements contained within PROD 3 of the PROD Sourcebook (the "**Product Governance Requirements**"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the Product Governance Requirements) may otherwise have with respect thereto, the Shares have been subject to a product approval process, which has determined that the Shares are: (i) compatible with an end target market of (a) investors who meet the criteria of professional clients and (b) eligible counterparties, each as defined in COBS 3.5 and 3.6 of the FCA's Conduct of Business Sourcebook; and (ii) eligible for distribution through all distribution channels as are permitted by the Product Governance Requirements (the "**Target Market Assessment**"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the Shares may decline and investors could lose all or part of their investment; the Shares offer no guaranteed income and no capital protection; and an investment in the Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Placing. Furthermore, it is noted that Cavendish will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of the Product Governance Requirements; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Shares and determining appropriate distribution channels.

By attending any presentation to which this document relates and/or by receiving this document (whether in hard copy form or electronically), you irrevocably represent, warrant and undertake to IXICO and Cavendish that: (i) you are a Relevant Person; (ii) you are not a U.S. Person nor acting on behalf of, or for the account or benefit of, a U.S. Person; (iii) you have read and agree to comply with, and be bound by, the contents of this notice; and (iv) you will not deal in (or encourage any other person to deal in) the Shares or base any behaviour on any inside information you receive as part of this presentation until you have ceased to have such information for the purposes of MAR.

IXICO – Established AI-driven neuroscience expertise

Seeking £10m Placing

A **leading iCRO** focussed exclusively on CNS

20 years of neuroscience expertise delivering gold standard clinical trial management and analysis



>80

employees ('IXICANs' - 27% PhDs)



28

current studies with...

17

leading global pharma, biotech & diagnostics Co's



>1,250

Onboarded imaging centres around the world utilising the IXI™ technology platform



core solutions: IXI™

born as a technology platform delivering AI analytics, biomarkers & diagnostic validation and trial management



Brain scans analysed

350,000+ across 40 countries




an AI-enabled platform for precision medicine



Standardised capture, analysis and reporting of regulatory compliant clinical data

Hospital


Pharma





IXICO– Business model

Delivering insights to Biopharma enabling 'make or break' decisions



Help biopharma make informed "high stake" program decisions with greater confidence



FY25 Traction - 2024 Fund Raise

'Innovate Lead Scale' to accelerate revenue growth

INNOVATE


Product differentiation
Technology expansion
Disease diversification

LEAD

Market visibility
Global footprint

SCALE

OB/Revenue growth
Expand serviceable market
New revenue streams



13% revenue growth

20% reduction in EBITDA loss

£3.5m cash

£17.5m order book (at 31/12/25)



RAG

FY25 investments & outcomes



New AD/PD product offerings



Deployment of next gen IXI™



TA diversification



Novel IXI™ applications & revenues



Heightened conference & marketing activity



Medical affairs & KOL expansion



US ops & commercial footprint expansion



Data partnerships



Existing project revenue expansion



New biomarker revenues



Order book growth



Pipeline expansion/conversion




Strategic partnerships



Company valuation

Growth Opportunity - 2026 Fund Raise

Leveraging the IXI™ technology to create true company value






Growth Opportunity - AI – Automation - Data



AI Sentiment & Disruption – Life Science Sector

What emerging trends do you think will have the most significant impact on your industry in the next 3–5 years?

(Select up to your top 3)



Source: Nature Partnerships, September 2025 | Life Sciences Market Outlook Whitepaper | 'Informed Optimism and Resilience in the Life Science Sector A snapshot of sentiment among senior global leaders about markets, business outlooks, AI and emerging trends

IXICO - positioning for future growth



Scale across the wider neurology precision medicine landscape

CLINICAL TRIAL MANAGEMENT

CLINICAL DECISION SUPPORT

*Examples of market participants



CUSTOMER

Biopharma

Health Systems


REV. MODEL

Service | Project | Licensing

Installed base licensing | Subscription

Future Growth – new routes to market

Leveraging clinical trial management ecosystem partners for new revenue streams using IXI™





IXICO™ partnership agreement



ONE-STOP-SHOP FOR CUSTOMERS

Single sign on | Standardised protocols | Integrated platforms | Low friction & familiarity (existing systems)

BioPharma



Global multi \$bn EDC platform

serving >35k+ trials across 140 countries



enterprise license £

IXICO BENEFIT


New route to market

Access to **size/scale**

PHASE 1 – integration



PHASE 2 – innovation

Image upload
Query handling





Addressable Growth Opportunity

The TechBio opportunity addressable market. Unlocking the **IXI** platform and removing barriers



Growth Opportunity – From bespoke services to scalable tech

		Revenue Growth	Value (x revenues)
<p>current</p>  <p>Advancing technology for use within IXICO to expand service offering</p>	<p>New algorithms & tools</p> <p>Combined imaging & BBB</p> <p>New CNS disease areas</p>	=15%	1-3x
<p>new</p>  <p>Enabling external organisations to directly access IXICO technology</p>	<p>Platform integration</p> <p>Platform automation</p> <p>Platform standardisation</p>	=25%	4-7x

Use of proceeds

Placing: £10m **Retail offer:** Up to £0.5m **Timing:** March 2026

VCT/EIS qualifying: Application for EIS Advance Assurance submitted via Philip Hare & Associates in respect of the £3m headroom under current EIS legislation. The balance of the raise that is seeking to be treated as VCT/EIS qualifying, will be conditional on a Philip Hare & Associates opinion letter following expected changes to the legislation from 6 April 2026.

PLATFORM (Integrate - Automate – Standardise)	£6.0m
<ul style="list-style-type: none"> • £3.0m platform and algorithm development staff • £1.7m Cloud, consultancy, IP & software costs • £1.3m Data, contract development and IT infrastructure 	
PARTNER (Partner – Sell)	£2.0m
<ul style="list-style-type: none"> • £0.5m Partnership integration staff • £0.5m Corp dev. staff • £0.3m Commercial staff • £0.7m Consultancy, KOL & marketing costs 	
PRODUCT (SaMD - QA – FDA)	£2.0m
<ul style="list-style-type: none"> • £0.7m Regulatory affairs staff • £1.0m Consultancy, regulatory, insurance, legal, training & conferences • £0.3m Clinical integration software 	

£1.5m CAPEX

£3.5m OPEX

£5.0m FTE

A team to deliver growth


Deepened expertise focused on global footprint expansion and revenue growth

Board Members

CEO



Bram Goorden*



Mark Warne (Chair)



Dipti Amin (NED)



Kate Rogers (NED)



Existing roles

HR



Hannah Esfahanian



Legal



Anna-Maria Moseley



QA/RA



John Green



Expanded roles

CFO / COO



Grant Nash*



CSO / CMO



Robin Wolz



CTO



Mark Austin



New roles

CBO



James Chandler



CCO




Tanya Voloshen



*Board member

Future Growth - Leveraging technology to create value





Investment summary

Scale across the wider neurology precision medicine landscape

- ✓ **Established iCRO for 20 years** – a market leader in CNS imaging, high scarcity value as a leading neuroimaging platform with cutting edge technology
- ✓ **Back on a clear growth trajectory** – Innovate Lead Scale strategy resulting in 15% revenue growth in a bigger serviceable market
- ✓ **Our phase 2 growth strategy** – accessing new revenue streams (beyond CRO) by partnering in the broader precision medicine ecosystem
- ✓ **Leverages AI technology** – our future proofed IXI™ platform can be equipped to broaden the reach of our biomarker algorithms by integrating our offering into larger partners' solutions
- ✓ **The £10m fundraise unlocks technology resources and removes barriers to scale** – enabling efforts to automate – standardise – integrate and eventually register as a medical device (SaMD)
- ✓ **Providing critical steps towards a value inflection point** – from 15% to 25% revenue growth and from 1-3 to 4-7 valuation multiples



Investment case – clear transformation strategy & execution



Financial performance

Strong revenue & OB growth

Scientific track record

Trusted expertise with book of loyal repeat business clients


Technology advantage


Full potential of differentiated technology platform unrealised

Market growth

Well positioned to take advantage of neurological market growth

VALUE CREATION

1. Maximise iCRO opportunity
2. Revenue expansion through  technology





Investor Relations:

james.chandler@ixico.com



IXICO plc
4th Floor, Griffin Court
15 Long Lane
London
EC1A 9PN